CARsgen Therapeutics

CARsgen Pharma (stock code: 2171.HK) is a biopharmaceutical company focused on developing innovative CAR-T cell therapies to address unmet clinical needs, including but not limited to hematological malignancies, solid tumors, and autoimmune diseases. The company has established end-to-end capabilities for CAR-T cell research and development, from target discovery, preclinical studies, and clinical development to commercial-scale manufacturing, making it one of the global CAR-T cell therapy research and development enterprises.

The company addresses the challenges of existing CAR-T cell therapies through self-developed novel technologies and a product pipeline with global rights, such as improving safety, enhancing efficacy in solid tumor treatment, and reducing treatment costs. As of June 30, 2025, the company holds over 300 patents, including 140 granted globally (including China, the U.S., Europe, and Japan). The company currently has 10 CAR-T pipeline products, including 4 autologous CAR-T and 6 allogeneic CAR-T, all self-developed with global rights. Among the autologous products, the fully human BCMA autologous CAR-T cell product, Saikeze® (Zevor-cel injection), has been approved for marketing in China. The company's Claudin18.2 autologous humanized CAR-T product, Shuricicel injection (CT041), has had its New Drug Application accepted by the National Medical Products Administration, and it is expected to become the world's first commercialized CAR-T product for solid tumors. In addition to autologous products, CARsgen is also advancing the development of multiple differentiated allogeneic CAR-T cell products.

CARsgen has established self-owned, vertically integrated manufacturing capabilities for three key stages of CAR-T production, including plasmid production, lentiviral vector production, and CAR-T cell manufacturing.

CARsgen's mission is to provide innovative and differentiated cell therapies for patients with cancer and other diseases globally, making cancer and other diseases curable.